Condition

Refractory Hodgkin Lymphoma (2)

Relapsed Hodgkin Lymphoma (2)

Overall Status

Active, not recruiting (1)

Recruiting (1)

Sign in for free

Phase

early phase 1 (1)

phase 2 (1)

Sponsor

ADC Therapeutics S.A. (1)

UNC Lineberger Comprehensive Cancer Center (1)

Collaborator

American Society of Clinical Oncology (1)

Intervention

camidanlumab tesirine (1)

nivolumab (1)

pembrolizumab (1)

Study Documents

Intervention Type

biological (1)

drug (1)

Funder Type

Industry (1)

Other (1)

Study Type

Interventional (2)

relapsed hodgkin lymphoma

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Worldwide (Camidanlumab Tesirine)

Active, not recruiting

Relapsed Hodgkin Lymphoma
Refractory Hodgkin Lymphoma

Camidanlumab Tesirine

Scottsdale, Arizona
+72 more

Dec 15, 2022

Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Chapel Hill (Nivolumab, Pembrolizumab)

Recruiting

Relapsed Hodgkin Lymphoma
Refractory Hodgkin Lymphoma

Nivolumab
Pembrolizumab

Chapel Hill, North Carolina

Lineberger Comprehensive Cancer Center at University of North Ca

Jul 22, 2022